ArticleCancer chemotherapy and pharmacology2021

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).

Fred Saad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.